INFI - Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

784 Memorial Drive
Cambridge, MA 02139
United States
617-453-1000
http://www.infi.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 22

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Adelene Q. Perkins	Chairman & CEO	850.97k	N/A	1960
Dr. Lawrence E. Bloch	Pres & Treasurer	541.66k	N/A	1966
Dr. Jeffery L. Kutok	Sr. VP & Chief Scientific Officer	N/A	N/A	1967
Mr. Seth A. Tasker	VP, Gen. Counsel & Sec.	354.18k	N/A	1979
Ms. Melissa Hackel	VP of Fin.	N/A	N/A	N/A

Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreement with Arcus Biosciences, Inc. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Corporate Governance

Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.